Treatment decisions for localized prostate cancer
Asking men what’s important
Cite this article as: Holmboe, E.S. & Concato, J. J GEN INTERN MED (2000) 15: 694. doi:10.1046/j.1525-1497.2000.90842.x Abstract OBJECTIVE: To identify what factors men consider important when choosing treatment for prostate cancer, and to assess why men reject watchful waiting as a treatment option. PARTICIPANTS: One hundred two consecutive men with newly diagnosed localized prostate cancer identified from hospital and community-based urology practice groups. MEASUREMENTS: Patients were asked open-ended questions about likes and dislikes of all treatments considered, how they chose their treatment, and reasons for rejecting watchful waiting. The interviews were conducted in person, after the men had made a treatment decision but before they received the treatment. MAIN RESULTS: The most common reasons for liking a treatment were removal of tumor for radical prostatectomy (RP) ( n=15), evidence for external beam radiation (EBRT) ( n=6), and short duration of therapy for brachytherapy (seeds) ( n=25). The most frequently cited dislikes were high risk of incontinence for RP ( n=46), long duration of therapy for EBRT ( n=29), and lack of evidence for seeds ( n=16). Only 12 men chose watchful waiting. Fear of future consequences, cited by 64% ( n=90) of men, was the most common reason to reject watchful waiting. CONCLUSION: In discussing treatment options for localized prostate cancer, clinicians, including primary care providers, should recognize that patients’ decisions are often based on specific beliefs regarding each therapy’s intrinsic characteristics, supporting evidence, or pattern of complications. Even if patients do not recall a physician recommendation against watchful waiting, this option may not be chosen because of fear of future consequences. Key words localized prostate cancer treatment decision making
Presented in part at the 1998 annual meeting of the Society for General Internal Medicine.
The opinions expressed herein are solely those of the authors and do not represent the views of the Department of Defense, the Department of the Navy, or the Department of Veterans Affairs.
Dr. Holmboe completed this work as a Fellow in the Robert Wood Johnson Clinical Scholars program, Yale University School of Medicine. Dr. Concato is supported by a Career Development Award from the VA Health Services Research and Development Service.
Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin. 1995;48:6–29.
Woolf SH. Screening for prostate cancer with prostate-specific antigen. N Engl J Med. 1995;333:1401–5.
Dorr VJ, Williamson SK, Stephens RL. An evaluation of prostatespecific antigen as a screening test for prostate cancer. Arch Intern Med. 1993;153:2529–37.
Perkins T. Concern grows over prostate cancer treatment options. JNCI. 1994;86:987–8.
Menon M, Parulker BG, Baker S. Should we treat localized prostate cancer. An opinion. Urology. 1995;46:607–15.
Walsh PC. The natural history of localized prostate cancer: a guide to therapy. In: Walsh PC, Retik AB, Vaughn ED, Wen AJ, eds. Campbell’s Urology. Philadelphia, PA: W.B. Saunders; 1998:2539–44.
Hahn DL, Roberts RG. Screening for asymptomatic prostate cancer: truth in advertising. J Fam Pract. 1993;37:432–6.
Litwin MS, Hays RD, Fink A., et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA. 1995;273:129–35.
Andriole GL, Smith DS, Rao G, Goodnough L, Catalona WJ. Early complications of contemporary anatomical radical retropubic prostatectomy. Urology. 1994;152(5 Pt 2):1858–60.
Fowler FJ, Roman A, Barry MJ, Wasson J, Lu-Yao G, Wennberg JE. Patient-reported complications and follow-up treatment after radical prostatectomy. The national Medicare experience: 1988–1990. Urology. 1993;42:622–9.
Garnick MB, Fair WR. Prostate cancer: emerging concepts. Part I. Ann Intern Med. 1996;125:118–25.
Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg JE. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA 1993;269:2650–8.
Schroder FH. Screening, early detection, and treatment of prostate cancer: a European view. Urology. 1995;46:62–70.
Graverson PH, Nielsen KT, Gasser TC, Corle DK, Madsen PO. Radical prostatectomy versus expectant primary treatment in stages I and II prostatic cancer. A fifteen year follow-up. Urology. 1990;36:493–8.
Middleton RG, Thompson IM, Austenfeld MS, et al. Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer. The American Urological Association. J Urol. 1995;154:2144–8.
Saltus R. For prostate cancer there’s no magic bullet. Boston Globe. January 12, 1998:C1.
Schapira MM, Nattinger AB, Katz DA, Lawrence W. Information seeking and satisfaction with treatment decision in patients with clinically localized prostate cancer. Med Decis Making. 1997;17(suppl):544. Abstract.
Fowler FJ, Bin L, Collins MM, et al. Prostate cancer screening and beliefs about treatment efficacy: a national survey of primary care physicians and urologists. Am J Med. 1998;104:526–32.
Feinstein AR. Clinimetrics. New Haven: Yale University Press; 1987.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.
D’Amico AV, Coleman CN. Role of interstitial radiotherapy in the management of clinically organ-confined prostate cancer: the jury is still out. J Clin Oncol. 1996;14:304–15.
Slovic P. Perception of risk. Science. 1987;236:280–5.
Kattan MW, Cowen ME, Miles BJ. A decision analysis for treatment of clinically localized prostate cancer. J Gen Intern Med. 1997;12:299–305.
Johansson JE. Watchful waiting for early stage prostate cancer. Urology. 1994;43:138–42.
Sandhu SS, Kaisary AV. Localised carcinoma of the prostate: a paradigm of uncertainty. Postgrad Med J. 1996;73:691–6.
Chodak GW. The role of watchful waiting in the management of localized prostate cancer. J Urol. 1994;152:1766–8.
Steinberg GD, Bales GT, Brendler CB. An analysis of watchful waiting for clinically localized prostate cancer. J Urol. 1998;159:1431–6.
PubMed CrossRef Copyright information
© Society of General Internal Medicine 2000